Fresh analysis reveals that patients who come off popular GLP-1 drugs like Wegovy and Mounjaro tend to recover reduced body mass much more quickly than those who stop traditional lifestyle plans.
Published data in a prominent medical journal demonstrates that while overweight people often shed about a fifth of their total mass while on the medication, the weight returns at an average rate of nearly a kilo each month after stopping.
"Individuals purchasing such treatments must be informed of the risk of fast rebound weight gain when the treatment ends," stated researcher Dr. Susan Jebb.
This pace of regain implies a return to starting weight within about 18 months.
Comparing Therapies
The analysis, which reviewed 37 of trials involving thousands of patients, contrasted the outcomes of these new drugs with other pills.
The team point out that individuals who shed pounds through diet and exercise typically have a slower weight regain—perhaps 0.1 kg a month—once they finish.
Explaining the Rapid Regain
Doctors propose the mode of action of the jabs explains the heightened weight return.
These medications imitate a natural hormone called glucagon-like peptide-1, which helps regulate hunger.
"Artificially providing GLP-1 levels far above than the body's typical production might result in the system to produce less of its own natural hormone, and could reduce sensitivity to its effects," said Dr. Adam Collins, a nutrition expert.
"Withdrawal of this GLP-1 'fix' leads to hunger is unsuppressed, making excessive eating much more probable."
A Lifelong Condition?
Medical guidelines suggest the jabs for people with obesity-related health risks, alongside recommended diet and exercise modifications.
Professionals argue that, due to the significant potential of relapse, the treatment might need to be life-long.
This perspective is echoed by pharmaceutical companies, who say that the findings "highlight the long-term nature of obesity," similar to managing diseases like high blood pressure.
User Accounts
Users who have come off the jabs describe a powerful resurgence of hunger.
"I experienced something flipping and you're instantly ravenous," recalled an individual.
This challenge is exacerbated if individuals have not developed permanent dietary or behavioural modifications during therapy.
Widespread Use
Figures indicate that millions of people in the UK have used these injections in the past year, with interest being substantial.
- Use is greater among women compared to men.
- The 40s and 50s age group shows the greatest level of interest.
- A large proportion access the drugs through private prescriptions rather than public health services.
In conclusion, researchers stress that while GLP-1 drugs are effective tools for weight loss, they are not a permanent fix and lasting health benefits likely depends on integrated lifestyle management.
